Alar Pharmaceuticals Inc.
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating t… Read more
Alar Pharmaceuticals Inc. (6785) - Total Assets
Latest total assets as of June 2024: NT$2.55 Billion TWD
Based on the latest financial reports, Alar Pharmaceuticals Inc. (6785) holds total assets worth NT$2.55 Billion TWD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Alar Pharmaceuticals Inc. - Total Assets Trend (2020–2023)
This chart illustrates how Alar Pharmaceuticals Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Alar Pharmaceuticals Inc. - Asset Composition Analysis
Current Asset Composition (December 2023)
Alar Pharmaceuticals Inc.'s total assets of NT$2.55 Billion consist of 92.8% current assets and 7.2% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 76.0% |
| Accounts Receivable | NT$0.00 | 0.0% |
| Inventory | NT$0.00 | 0.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2020–2023)
This chart illustrates how Alar Pharmaceuticals Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alar Pharmaceuticals Inc.'s current assets represent 92.8% of total assets in 2023, a decrease from 97.9% in 2020.
- Cash Position: Cash and equivalents constituted 76.0% of total assets in 2023, down from 92.9% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Alar Pharmaceuticals Inc. Competitors by Total Assets
Key competitors of Alar Pharmaceuticals Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Alar Pharmaceuticals Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Alar Pharmaceuticals Inc. generates 0.48x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Alar Pharmaceuticals Inc. generates $ 39.32 in net profit.
Alar Pharmaceuticals Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 39.65 | 3.52 | 3.63 |
| Quick Ratio | 39.65 | 3.52 | 3.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$2.39 Billion | NT$ 446.92 Million | NT$ 458.73 Million |
Alar Pharmaceuticals Inc. - Advanced Valuation Insights
This section examines the relationship between Alar Pharmaceuticals Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.38 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | 86.2% |
| Total Assets | NT$973.21 Million |
| Market Capitalization | $208.85 Million USD |
Valuation Analysis
Below Book Valuation: The market values Alar Pharmaceuticals Inc.'s assets below their book value (0.21 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Alar Pharmaceuticals Inc.'s assets grew by 86.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Alar Pharmaceuticals Inc. (2020–2023)
The table below shows the annual total assets of Alar Pharmaceuticals Inc. from 2020 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | NT$973.21 Million | +86.22% |
| 2022-12-31 | NT$522.60 Million | -3.20% |
| 2021-12-31 | NT$539.91 Million | -10.61% |
| 2020-12-31 | NT$603.98 Million | -- |